Literature DB >> 27638048

Appraisal of role of the polyanionic inducer length on amyloid formation by 412-residue 1N4R Tau protein: A comparative study.

Abolfazl Jangholi1, Mohammad Reza Ashrafi-Kooshk2, Seyed Shahriar Arab3, Gholamhossein Riazi4, Farzad Mokhtari4, Mansour Poorebrahim5, Hamid Mahdiuni6, Boris I Kurganov7, Ali Akbar Moosavi-Movahedi4, Reza Khodarahmi8.   

Abstract

In many neurodegenerative diseases, formation of protein fibrillar aggregates has been observed as a major pathological change. Neurofibrillary tangles, mainly composed of fibrils formed by the microtubule-associated protein; Tau, are a hallmark of a group of neurodegenerative diseases such as Alzheimer's disease. Tau belongs to the class of natively unfolded proteins and partially folds into an ordered β-structure during aggregation. Polyanionic cofactors such as heparin are commonly used as inducer of Tau aggregation in vitro. The role of heparin in nucleation and elongation steps during Tau fibril formation is not fully understood. In the current study, aggregation kinetics as well as structure of Tau amyloid fibrils, by using the 1N4R isoform, have been reproducibly determined in the presence of heparin and the shorter molecule; enoxaparin. The kinetic studies demonstrated that heparin (not enoxaparin) efficiently accelerates Tau amyloid formation and revealed, mechanistically, that the molecular weight of the inducer is important in accelerating amyloidogenesis. The kinetic parameter values of Tau amyloid aggregation, especially, the amyloid aggregation extent, were relatively different in the presence of heparin and enoxaparin, at various stoichiometries of the inducers binding. Also, based on the results, obtained from CD, FTIR, AFM and XRD studies, it may be suggested that the inducer length plays a critical role mainly in the nucleation process, so that it determines that oligomers lie on or off the pathway of Tau fibrillization. The biochemical results herein suggest that the chemical environment of the extracellular matrix as well as localization of distinct glycosaminoglycans may influence deposition behavior of Tau amyloidosis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  1N4R Tau isoform; Amyloid aggregation; Enoxaparin; Heparin

Mesh:

Substances:

Year:  2016        PMID: 27638048     DOI: 10.1016/j.abb.2016.09.004

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

Review 1.  Amyloidogenesis of Tau protein.

Authors:  Bartosz Nizynski; Wojciech Dzwolak; Krzysztof Nieznanski
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

2.  Glycan Determinants of Heparin-Tau Interaction.

Authors:  Jing Zhao; Isabelle Huvent; Guy Lippens; David Eliezer; Anqiang Zhang; Quanhong Li; Peter Tessier; Robert J Linhardt; Fuming Zhang; Chunyu Wang
Journal:  Biophys J       Date:  2017-03-14       Impact factor: 4.033

3.  The distinct structural preferences of tau protein repeat domains.

Authors:  Xuhua Li; Xuewei Dong; Guanghong Wei; Martin Margittai; Ruth Nussinov; Buyong Ma
Journal:  Chem Commun (Camb)       Date:  2018-05-31       Impact factor: 6.222

4.  Unravelling the Novel Effects of Three Volatile Compounds in Preventing Fibril Formation of Disease Related Tau and α-Synuclein Proteins- Towards Identifying Candidate Aromatic Substances for Treating Neurodegenerative Diseases.

Authors:  Zahra Moeini; Zahra Seraj; Toktam Zohoorian Abootorabi; Mohammadreza Ashrafi-Kooshk; Gholamhossein Riazi; Ali Akbar Saboury; Arefeh Seyedarabi
Journal:  Front Pharmacol       Date:  2022-03-22       Impact factor: 5.810

5.  Inhibition Of Tau Protein Aggregation By a Chaperone-like β-Boswellic Acid Conjugated To Gold Nanoparticles.

Authors:  Masoumeh Gharb; Amideddin Nouralishahi; Ali Riazi; Gholamhossein Riazi
Journal:  ACS Omega       Date:  2022-08-18

6.  Cannabidiol Inhibits Tau Aggregation In Vitro.

Authors:  Soha Alali; Gholamhossein Riazi; Mohammad Reza Ashrafi-Kooshk; Sogol Meknatkhah; Shahin Ahmadian; Mohammad Hooshyari Ardakani; Baharak Hosseinkhani
Journal:  Cells       Date:  2021-12-13       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.